Nano-emulsion technology for drug elution

ABSTRACT

Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended polymer matrix. Such methods and materials can be used for example to assess and control the manufacturing process variability of drug eluting implantable devices such as cardiac leads.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is related to U.S. patent application Ser. No.11/881,074 filed Jul. 25, 2007, the contents of which are incorporatedby reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to media used in drug elution studies andmethods for making and using them.

2. Description of Related Art

The implantation of a medical device into a patient's body can cause thebody to exhibit adverse physiological reactions ranging from infectionsto the formation of emboli or clots in blood vessels. One approach toaddress such reactions and improve the biocompatibility of such medicaldevices is to incorporate bioactive or pharmacological agents such assteroids, and/or antibiotics and/or anticoagulants onto a surface ofthese devices. Once implanted, these agents can then elute into the invivo environment at the site of implantation and modify thephysiological response.

Exemplary medical procedures that involve the implantation of medicaldevices include those designed to modulate cardiac physiology. Forexample, a variety of systems that use one or more pacing leads withelectrodes such as cardiac rhythm management (CRM) systems and varioustechniques for implanting these lead systems in contact body tissue suchas the heart, have been developed. In this context, the safety, efficacyand longevity of an electrical pulse generator of a CRM depends, inpart, on the performance of the associated cardiac lead(s) used inconjunction with the pulse generator. For example, various properties ofthe lead and electrodes will result in a characteristic impedance andstimulation threshold. Stimulation threshold is the energy required in astimulation pulse to depolarize, or “capture,” the heart tissue. Arelatively high impedance and low threshold is desired to minimize thecurrent drawn from a pulse generator battery in delivering a stimulationpulse. Another example may be when implanting a medical device, it canresult in infections in the area of infections. Such infections can bereduced by coating or otherwise combining an antibiotic with theimplanted device.

One factor that can affect the stimulation threshold, particularlyduring the first several weeks after implantation of a lead, is thenatural immunological response of the body to the lead as a foreignobject. The presence of the lead activates macrophages, which attachthemselves to the surface of the lead and any electrodes and formmulti-nucleated giant cells. These cells, in turn, secrete varioussubstances, such as hydrogen peroxide as well as various enzymes, in aneffort to dissolve the foreign object. Such substances, while intendingto dissolve the foreign object, also inflict damage to the surroundingtissue. When the surrounding tissue is the myocardium, these substancecause necrosis. These areas of necrosis, in turn, impair the electricalcharacteristics of the electrode-tissue interface. Consequently pacingthresholds rise. Even after the microscopic areas of tissue die theinflammatory response continues and approximately seven days afterimplant the multi-nucleated giant cells cause fibroblasts to beginlaying down collagen to replace the necrotic myocardium. Eventually, onthe order of three weeks after implant, the lead and its electrodes canbe encapsulated by a thick layer of fibrotic tissue. Typically, theinflammatory response ends at this time. The fibrotic encapsulation ofthe lead and its electrodes, however, remains. Since the fibrotic tissueis not excitable tissue, an elevated stimulation threshold can persistdue to the degraded electrical properties of the electrode-tissueinterface.

One means of modulating this inflammatory response in implanted cardiacrhythm management systems has been to provide a drug near the electroniclead to mitigate the inflammatory tissue reaction described above. Inparticular, it has been found devices designed to elute ananti-inflammatory agent, such as a glucocorticoid steroid, minimizetissue irritation, help reduce or eliminate threshold peaking andfurther assist in maintaining low acute and chronic pacing thresholds. Aconsiderable breakthrough in the development of low threshold electrodetechnology occurred with the invention of the steroid eluting pacingelectrode of Stokes U.S. Pat. No. 4,506,680 and related Medtronic U.S.Pat. Nos. 4,577,642, and 4,606,118. Steroid, it is believed, inhibitsthe inflammatory response by inhibiting the activation of themacrophages. Because they do not form multi-nucleated giant cells, thesubsequent release of substances to dissolve the object and which alsodestroy the surrounding tissue is prevented. Thus, the necrosis of anytissue by the inflammatory response is minimized as well as theformation of the fibrotic capsule. Minimizing such adverse reactions ishighly desirable because it also minimizes the concomitant deteriorationof the electrical characteristics of the electrode-tissue interface. Theincorporation of a compound such as a steroid that elutes at the site ofimplantation permits pacing leads to have a source impedancesubstantially lower as compared to leads featuring similarly sized solidelectrodes. Consequently, electronic leads which can elute compoundssuch as steroids also present significantly lower peak and chronicpacing thresholds than similarly sized electrodes and have thereforebeen adapted for patient treatment in a variety of contexts.

Implantable compositions which elute a steroid can include a drugblended with a polymeric material such as dexamethasone impregnatedwithin a silicone polymer, a blended composition that is designed toslowly elute the steroid out of the polymer and into the surroundingtissue. Incorporating a drug such as a steroid into a device so that itwill elute from a device upon implantation, however, increases thecomplexity of electronic device production as compared to non-steroideluting devices. One potential area of difficulty in this context is thepossibility of variable manufacturing processes and the potentialassociated effects on elution kinetics. In this context, methods andmaterials that allow artisans to readily examine the drug elutionproperties of electronic devices and other drug eluting medical devicesare highly desirable. Such methods and materials can be used for exampleto assess manufacturing process variability of drug eluting implants andthe associated quality control of such processes. Moreover, while realtime in vivo elution studies may be necessary to gain a comprehensivemechanistic understanding of the modulation of the physiologicalreactions observed with implantation, such real time elution tests canbe on the order of weeks or months. Consequently, accelerated in-vitrotests that correlate with such tests are important for manufacturing andquality control processes. For this reason, methods and materials suchas media and apparatuses that can be used to assess and control themanufacturing process variability of drug eluting implantable devicesare highly desirable.

SUMMARY OF THE INVENTION

Embodiments of the invention provide apparatuses and media useful fordrug elution studies and methods for making and using them. The mediaand associated methods disclosed herein are designed for the elution ofagents impregnated within a polymer matrix. Such methods and materialscan be used, for example, to assess and control the manufacturingprocess variability of drug eluting implantable devices such as cardiacleads.

One embodiment of the invention is a drug elution method that can beused for in-vitro studies of a matrix impregnated with a compound suchas a drug blended polymer matrix. Illustrative embodiments of theinvention include methods that use a unique dissolution media to observethe elution of dexamethasone acetate from a blended polymer, a matrixthat can be used for example with drug loaded pace maker leads. Thisdissolution media uses a combination of constituents designed to elutecompounds from within a matrix effectively and efficiently over arelatively short period of time. This dissolution media and methods forusing it consequently provide an in-vitro platform for productdevelopment and quality control, particularly in the production of drugcoated medical devices.

An illustrative embodiment of the invention is a method for observingthe elution of a compound from a matrix using a form of a nano-emulsiontechnique, the method comprising exposing the matrix comprising thecompound to a solution comprising: phosphate buffered saline having a pHrange of pH 5 to pH 7; 1-9% limonene; 0.3-9% sodium dodecyl sulfate; and0.5-15% lower alkanol; and then assaying the solution for the presenceof the compound so as to observe the elution of the compound from thematrix into the solution (e.g. via a chromatographic separationtechnique such as HPLC). In some embodiments of the invention, the loweralkanol is ethanol or n-butanol. In certain embodiments, the solutioncomprises phosphate buffered saline at pH 6; 3-5% limonene; 3-5% sodiumdodecyl sulfate; and 1-3% n-butanol.

The methods of the invention can be used to study the elution of a widevariety of compounds from a wide variety of matrices. For example, themethod can be used to study a plastic or other polymeric matrix havingthe compound impregnated, coated or embedded therein. In an illustrativeembodiment, the matrix can comprise a polymer such as a silicone polymerand the compound can comprise a steroid, an anti-coagulant anantibiotic, or an anti-inflammatory agent. In an illustrative embodimentprovided in the examples below, the matrix is a biomedical gradesilicone polymer impregnated with dexamethasone acetate. Typically, thematrix and the compound are adapted for implantation in vivo, forexample as part of an electronic lead of a pacemaker.

In typical embodiments of the invention, the methods are adapted tofacilitate processes such as the product development and quality controlof implantable drug coated medical devices. In such embodiments, themethod can be practiced on a plurality of matrices produced according toa uniform manufacturing process, typically one designed to produce aplurality of matrices that elute the compound at the same rate.Optionally, the method can include the step of comparing the elutionrates of two or more of plurality of matrices to determine if the two ormore matrices have the same or different elution rates.

A related embodiment of the invention is a composition of mattercomprising a solution of phosphate buffered saline having a pH range ofpH 5 to pH 7; 1-9% limonene; 0.3-9% sodium dodecyl sulfate; and 0.5-15%lower alkanol. In certain embodiments of this composition, the loweralkanol is ethanol or n-butanol. Optionally in this composition, thesolution comprises phosphate buffered saline having a pH of 6, 3-5%limonene; 3-5% sodium dodecyl sulfate; and 1-3% n-butanol.

In some embodiments of the invention, the composition of matter furthercomprises a matrix impregnated with an elutable agent comprising asteroid, an anti-coagulant an antibiotic, or an anti-inflammatory agent.Optionally for example, the matrix is a polymer matrix impregnated withdexamethasone acetate. In one illustrative embodiment of the invention,the composition of matter further comprises a polymer matrix adapted foruse as part of a cardiac lead.

Other objects, features and advantages of the present invention willbecome apparent to those skilled in the art from the following detaileddescription. It is to be understood, however, that the detaileddescription and specific examples, while indicating some embodiments ofthe present invention are given by way of illustration and notlimitation. Many changes and modifications within the scope of thepresent invention may be made without departing from the spirit thereof,and the invention includes all such modifications.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B show typical plots of the elution of dexamethasoneacetate from Controlled Release Devices (CRD).

FIG. 2 shows a logarithmic plot of drug elution in Device 1.

FIG. 3 shows dexamethasone elution data from three different lots of CRD1 (nominal process).

FIG. 4 shows a discriminatory study of the elution of dexamethasoneacetate from CRD 1.

FIG. 5 shows a discriminatory study of the elution of dexamethasoneacetate from a second CRD.

FIG. 6 shows an embodiment of an apparatus designed to inhibit fluidloss due to evaporation from a fluid dissolution vessel. This specificembodiment of the apparatus (10) comprises a cap (20) for engaging avessel (30). The central diagram shows a group of four caps operativeengaged with vessels and various interactive elements of the apparatus.The diagram at the upper right shows the cap not engaged with a vesseland/or various interactive elements of the apparatus. In the embodimentof the invention shown in this figure, the cap has a first external side(40) and a second internal side (50) that is exposed to a fluidcontained in the vessel. The second side (50) comprises a conical member(60) that is designed to direct a condensate that has condensed from thefluid in the vessel onto the second side of the cap back into the fluid.The cap includes a flange (70) disposed between the first external sideand the second internal side of the cap. This embodiment shows a centralport (80) disposed in the cap adapted to receive a rotatable rod (90),where the material of the central port (typically Teflon) and thematerial of the rotatable rod are in close contact so as to create aseal that inhibits escape of a material contained within the vessel intothe external environment. The rotatable rod in this embodiment includesa fluid agitation member (170) at the distal end of the rod thatagitates fluid within the vessel. In this embodiment, the central port(80) is disposed in a central washer (120) that is further disposedwithin a central washer port (130) on the cap. This embodiment shows asample port (100) disposed in the cap to allow a user to obtain a sampleof the solution from the vessel (or to introduce a composition into thevessel) via a cannula (not shown). In this embodiment, the sample port(100) is disposed in a sample port washer (110) that is further disposedin a sample washer port (160). The sample port washer (110) furtherincludes a cannula securing port (140) that receives a tightening screwmember (not shown) that can be used to secure a cannula inserted intothe sample port (100) at a desired position. This embodiment furthershows a temperature member port (150) adapted to allow a user tointroduce a temperature member that contacts and monitors thetemperature of the solution within the vessel. The temperature memberport (150) is adapted to receive a temperature port cap (210) that cancover the temperature port to inhibit escape of a material within thevessel into the external environment. All of the interacting componentsin this embodiment of the cap (20) are constructed to closely fittogether so as to create seals that inhibits escape of a material withinthe vessel into the external environment. In addition, a sealing member(not shown) that contacts the vessel (30) that contains the fluid canalso be disposed on the cap (20) so as to create a seal with the vesselthat inhibits escape of a material within the vessel into the externalenvironment when the cap is operatively engaged with the vessel. Theembodiment of the apparatus in this figure further shows a clamp (180)that secures the cap to the vessel via a clamp screw member (190) aswell as a rack (200) constructed to hold a plurality of vessels.

FIG. 7A provides a graph showing a comparison of elution profiles of asteroid from drug eluting lead components over about 15 days using amedia embodiment of the invention comprising 5% R(+) Limonene, 5% SDS,and 2% n-butanol in PBS pH 6. This graph provides a discriminatory studywith the drug impregnated matrix made according to the Nominal processas well as Process Variation 1 and Process Variation 2. FIG. 7B providesa graph showing a comparison elution profiles of a steroid from drugeluting leads over about 50 days using a media embodiment of theinvention comprising 5% R(+) Limonene, 5% SDS, and 2% n-butanol in PBSpH 6. This graph provides a discriminatory study with the drugimpregnated matrix made according to the nominal process as well asprocess variation 1.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Unless otherwise defined, all terms of art, notations and otherscientific terms or terminology used herein are intended to have themeanings commonly understood by those of skill in the art to which thisinvention pertains. In some cases, terms with commonly understoodmeanings are defined herein for clarity and/or for ready reference, andthe inclusion of such definitions herein should not necessarily beconstrued to represent a substantial difference over what is generallyunderstood in the art. Many of the techniques and procedures describedor referenced herein are well understood and commonly employed usingconventional methodology by those skilled in the art. As appropriate,procedures involving the use of commercially available kits and reagentsare generally carried out in accordance with manufacturer definedprotocols and/or parameters unless otherwise noted.

A. Methods and Media for Observing Drug Elution from a Matrix

The invention disclosed herein has a number of embodiments. Oneembodiment of the invention is a drug elution method that can be usedfor in-vitro studies of a matrix impregnated with a compound such as adrug blended polymer matrix. Specific embodiments of the inventioninclude methods that use a unique dissolution media to observe theelution of dexamethasone acetate from a drug blended polymer matrix, amatrix that is used for example with drug loaded pace maker leads. Thisdissolution media uses a combination of constituents designed to elutecompounds from within a matrix effectively and efficiently over arelatively short period of time. This dissolution media and methods forusing it consequently provide an in-vitro platform for productdevelopment and quality control, particularly in the production of drugcoated medical devices.

In the examples below, the disclosure provides illustrative embodimentsof the methods of invention that examine the elution of dexamethasonefrom a polymeric silicone matrix. This example provides an illustrationof the power of the methods of the invention, in particular in view ofthe fact that the elution of dexamethasone acetate from siliconepolymer/drug coated pace maker leads is known to be minimal inconventional solvents. In this context, the elution media dissolutionsolution includes limonene. As is known in the art, limonene assumesisomeric forms such as (R)-(+)-Limonene and (S)-(−)-limonene. Optionallythe limonene used in embodiments of the invention is a single isomer oralternatively a combination of limonene isomers. In typical embodimentsof the invention, a single limonene isomer is used which is(R)-(+)-limonene. The addition of limonene provides a unique dissolutionmedia additive that dramatically increases the dissolution ofdexamethasone acetate from matrices such as the drug coated pace makerleads. Without being bound by a specific scientific theory, it appearsthat the limonene swells the polymer and helps in eluting a drug such asdexamethasone acetate from a matrix such as drug coated pace makerleads. As any matrix comprising a compound can be tested using thedisclosed methods and materials, the methods of the invention areapplicable to a wide variety of other contexts where it is desirable toobserve the elution of a compound from a matrix.

Embodiments of the invention include an elution media containing acosolvent in the form of a lower alkanol. As used herein the term“alkanol” refers to alkanes (saturated hydrocarbons with straight orbranched chain structures, with general formula CnH2n+2) having ahydroxyl group (—OH) moiety. As used herein the term “lower alkanol”refers to alkanols having 1-8 carbon atoms such as methanol, ethanol,propanol, butanol, pentanol, hexanol, heptanol, octanol or mixturesthereof. The term “lower alkanol” includes both straight chain alkanolshaving 1-8 carbon atoms such as 1-propanol (also known in the art asn-propanol) and 1-butanol (also known in the art as n-butanol) etc. aswell as isomers such as isopropanol, isobutanol, sec-butanol, tertbutanol etc. In illustrative embodiments of the invention, the loweralkanol is ethanol or n-butanol.

Surprisingly, the addition of a lower alkanol cosolvent provides anelution media with unexpectedly desirable elution properties, forexample an enhanced ability to elute agents that are tightly complexedwithin a matrix, for example a drug complexed within a polymer matrix.Without being bound by a specific scientific theory, it is believed thatthe lower alkanol cosolvent functions to stabilize the micellestructures formed by the components of the elution media and/or allowthe formation of smaller micelle structures in a manner that allows themicelles to penetrate deeper into a matrix structure and elute an agentimpregnated therein. In addition (and perhaps consequently), theinclusion of a lower alkanol cosolvent allows the elution media toinclude higher concentrations of both SDS and limonene.

The methods and compositions of the invention can be used in a varietyof contexts and are particularly well suited for studies of materialsvariations that can occur for example within a batch of processedmaterials and/or between batches of processed material. The term “batch”is used according to its art accepted meaning and refers to a specificquantity of a drug or other material produced (typically according to asingle manufacturing order during the same cycle of manufacture) andintended to have uniform character and quality, within specified limits.As shown in the examples below, this dissolution media is proven to bediscriminatory for detecting process variations in manufacturingprocesses.

While the methods of the invention can be used to assess the elution ofa wide variety of compounds from a wide variety of matrices, thesemethods of the invention are particularly useful in the context of themanufacture of drug eluting implantable medical devices. For example,the safety and efficacy of drug coated pace maker leads are readilyevaluated using the unique dissolution methods and materials disclosedherein. In contrast, due to the extended release nature of the productand also due to the poor solubility of dexamethasone acetate, theelution of the drug is observed to be minimal in conventionaldissolution media, for example a media that utilizes just a surfactant.

A typical embodiment of the invention is a method for observing theelution of a compound from a matrix comprising the compound into asolution. In typical embodiments of this method, the solution comprisesphosphate buffered saline having a pH range of pH 5 to pH 7; 1-9%limonene; 0.3-9% sodium dodecyl sulfate and 0.5-15% lower alkanol. In anexemplary embodiment of this method, the solution comprises phosphatebuffered saline having a pH of 6, 3-6% limonene; 3-6% sodium dodecylsulfate, and 1-3% 1-butanol. Typically, the method comprises combiningthe matrix comprising the compound with the solution and then observingthe elution of the compound from the matrix into the solution over time.

This solution and method can be used in the evaluation of manufacturingprocesses, for example to confirm that samples from various batches haveelution properties within a set of characteristic parameters. Someembodiments of the invention may include a 1-9% limonene solution and0.5-15% lower alkanol as well as other components known in the art andused in elution studies, for example acetate buffer having a pH range ofpH 5 to pH 7 and/or anionic (e.g. sodium dodecyl sulfate), cationic(e.g. Cetyl trimethyl ammonium bromide—CTAB) and non-ionic (e.g. SolutolHS 15-poly-oxyethylene esters of 12-hydroxystearic acid, Tween 80)surfactants.

Embodiments of the method can be manipulated by modifying the conditionsunder which elution is observed, for example, by observing elution at aspecific solution temperature or temperature range, e.g. at 25, 30, 37,40 or 45 degrees centigrade or between 25 and 45 degrees centigrade. Inaddition, typical embodiments of the invention include the steps ofagitating the solution with a stirring device, shaker or use a flowthrough device like USP apparatus 4. Typically, the volume of thesolution used in such methods is between 50 and 150 milliliters (e.g.50, 75, 100, or 125 milliliters). In some embodiments of the invention,the specific formulation of the media is selected for specific elutioncharacteristics, for example, an ability to elute at least 50% ofdexamethasone acetate impregnated within a polymeric silicone matrix in72 hours at 37 degrees centigrade.

In describing this invention, the term “matrix” simply means anymaterial in which a compound can be coated on to, and/or combined withand/or embedded within and/or enclosed within. Similarly, the “matrixcomprising the compound” is a material having a compound such as asteroid and/or anticoagulant and/or antibiotic or the like loaded and/orcoated on it and/or embedded within it and/or enclosed within it. Suchmethods for observing the elution of a compound from a matrix byexposing the compound to a solution and then observing the presence ofthe compound in the solution over a period of time can be used toobserve a wide variety of matrices and compounds. Such assays can beused to determine what percentage of a compound (e.g. 0% up to 100% of adrug loaded compound) is eluted under specific conditions (e.g.concentration of various components of the media and/or pH and/ortemperature etc.) over various periods of time (e.g. 1 minute, 1 hour, 1day or 1 week etc.).

Elution of a compound from a wide variety of matrices are known in theart can be observed in the methods of the invention. In typicalembodiments of the invention, the matrix is an implantable polymermatrix. Typically, polymer matrices observed in the methods of theinvention are biocompatible and designed to minimize irritation at thesite of implantation. In certain embodiments of the invention, thepolymer may be either a biostable or a bioabsorbable polymer dependingon the desired rate of release or the desired degree of polymerstability. Biostable polymers such as polyurethanes, silicones, andpolyesters are used in certain embodiments of the invention. In theexamples provided below, the illustrative matrix used to demonstrateembodiments of the invention is a biomedical silicone polymerimpregnated with dexamethasone. Other polymers can also be used incertain embodiments of the invention such as polyolefins,polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymersand copolymers, vinyl halide polymers and copolymers, such as polyvinylchloride; polyvinyl ethers, such as polyvinyl methyl ether;polyvinylidene halides, such as polyvinylidene fluoride andpolyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinylaromatics, such as polystyrene, polyvinyl esters, such as polyvinylacetate; copolymers of vinyl monomers with each other and olefins, suchas ethylene-methyl methacrylate copolymers, acrylonitrile-styrenecopolymers, ABS resins, and ethylene-vinyl acetate copolymers;polyamides, such as Nylon 66 and polycaprolactam; alkyd resins;polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins,polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate,cellulose butyrate; cellulose acetate butyrate; cellophane; cellulosenitrate; cellulose propionate; cellulose ethers; and carboxymethylcellulose. Bioabsorbable polymers include poly(L-lactic acid),polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate),poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester,polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolicacid-co-trimethylene carbonate), polyphosphoester, polyphosphoesterurethane, poly(amino acids), cyanoacrylates, poly(trimethylenecarbonate), poly(iminocarbonate), copoly(ether-esters) (e.g. PEO/PLA),polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin,fibrinogen, cellulose, starch, collagen and hyaluronic acid. In otherembodiments of the invention, the matrix can be a metal such as one ofthe metals typically used in portions of implantable medical devicesthat are exposed to living tissue.

A wide variety of compounds can be coated on to, and/or combined withand/or embedded within and/or enclosed within a matrix to produce amatrix comprising the compound. For example, the compound used in thepresent invention can be virtually any compound which possessesdesirable therapeutic characteristics for implantation. In someembodiments, the compound is a glucocorticoid such as dexamethasone,dexamethasone sodium phosphate, dexamethasone acetate or anotherdexamethasone derivative as well as related molecules such asbeclamethasone or betamethasone. In one illustrative embodiment of theinvention, the matrix comprising the compound is a matrix having thecompound blended therein, for example a 60-80% silicone polymer (e.g. abiomedical grade silicone polymer) impregnated with a compound such asdexamethasone acetate.

As noted above, wide range of matrix and compound materials known in theart can be studied in the methods of the invention including metal,plastic and other polymeric matrices as well as compounds such as asteroid, an anti-coagulant an antibiotic, or an anti-inflammatory agent,for example heparin or another thrombin inhibitor, hirudin, hirulog,argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, oranother antithrombogenic agent, or mixtures thereof; urokinase,streptokinase, a tissue plasminogen activator, or another thrombolyticagent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor;a calcium channel blocker, a nitrate, nitric oxide, a nitric oxidepromoter or another vasodilator; an antimicrobial agent or antibiotic;aspirin, ticlopdine, a glycoprotein IIb/IIIa inhibitor or anotherinhibitor of surface glycoprotein receptors, or another antiplateletagent; colchicine or another antimitotic, or another microtubuleinhibitor, dimethylsulfoxide (DMSO), a retinoid or another antisecretoryagent; cytochalasin or another actin inhibitor; or a remodellinginhibitor; deoxyribonucleic acid, an antisense nucleotide or anotheragent for molecular genetic intervention; methotrexate or anotherantimetabolite or antiproliferative agent; an anti-cancerchemotherapeutic agent; dexamethasone, dexamethasone sodium phosphate,dexamethasone acetate, belcomethasone (e.g. belcomethasone dipropionate)or another dexamethasone analog or derivative, or anotheranti-inflammatory steroid or non-steroidal antiinflammatory agent;cyclosporin or another immunosuppressive agent; trapidal (a PDGFantagonist), angiopeptin (a growth hormone antagonist), an anti-growthfactor antibody, or another growth factor antagonist; dopamine,bromocriptine mesylate, pergolide mesylate or another dopamine agonistradiotherapeutic agents; iodine-containing compounds, barium-containingcompounds, gold, tantalum, platinum, tungsten or another heavy metalfunctioning as a radiopaque agent; a peptide, a protein, an enzyme, anextracellular matrix component, a cellular component or another biologicagent; captopril, enalapril or another angiotensin converting enzyme(ACE) inhibitor; ascorbic acid, alphatocopherol, superoxide dismutase,deferoxamine, a 21-aminosteroid (lasaroid) or another free radicalscavenger, iron chelator or antioxidant of any of the foregoing; or amixture of any of these. The ratio of compound to the matrix (e.g. atherapeutic substance such as dexamethasone to a silicon polymer) willvary according to how the compound and matrix are used. A wide ratio ofcompound to matrix ratios can therefore be appropriate and can rangefrom about 10:1 to about 1:100.

As discussed above, the methods of the invention can be used to studymatrices impregnated and/or coated with compounds that are used orimplanted in vivo including those used with pacemaker leads (e.g. inrings and tips for leads), stents, sensors, medication delivery pumps,catheters, balloons, wire guides, cannulae, and the like) and in vivoand ex vivo antimicrobial coatings and similar coatings and covers. Inaddition, the methods and materials of the invention can be used toassay matrices and compounds that are not implanted, such as a matrixcomprising a compound that is used in industrial application, forexample, compound impregnated matrices used in fermentation processes.Embodiments of the invention are adapted for observing matrices producedin batches according to one or more carefully controlled manufacturingprocesses (e.g. as part of a manufacturing process controlled inaccordance with FDA guidelines). An exemplary embodiment of theinvention involves performing the method on a plurality of matricesproduced according to a uniform manufacturing process. A relatedembodiment of the invention involves performing the method on aplurality of such matrices made by a process designed to produce aplurality of matrices that elute the compound at the same rate. Anotherembodiment of this method involves further analytical steps, for examplecomparing the elution rates of two or more of plurality of matrices todetermine if the two or more matrices have the same or different elutionrates.

A wide variety of methods known in the art can be used to observe thecompound in the solution including chromatographic methods such as HPLCand the like as well as immunoassays such as enzyme linkedimmunoadsorbent assays and the like. In view of the level of skill inthis art, artisans can use any one or a wide variety of detectiontechniques and/or any separation technique followed by detection.Illustrative but non-limiting examples of such techniques includecapillary electrophoresis, HPLC-UV; HPLC-MS (MS=Mass Spectroscopy);HPLC-UV (UPLC=Ultra performance LC) and; if for example the drug isvolatile, techniques such as gas chromatography-flame ionizationdetection (GC/FID) in GC/FID, the FID or flame ionization detectordetects analytes by measuring an electrical current generated byelectrons from burning carbon particles in the sample. See, e.g. HPLCMethod Development for Pharmaceuticals, Volume 8 (Separation Science andTechnology), 2007 Academic Press, 1^(st) ed., Ahuja and Rasmussen(Editors); and Handbook of HPLC (Chromatographic Science), 1998, MarcelDekker 1^(st) ed. Katz et al eds.

Related embodiments of the invention include compositions of matter: (1)made for; or (2) produced by the methods disclosed above, for example, acomposition of matter comprising a solution of phosphate buffered salinehaving a pH range of pH 5 to pH 7; 1-9% limonene; 0.3-9% sodium dodecylsulfate; and 0.5-15% lower alkanol. Certain specific embodiments of thiscomposition of matter further comprise a polymer matrix impregnated witha steroid or anti-coagulant. In this context, artisans will understandthat a wide variety permutations of such solutions can be readily madewith minimal effort, for example phosphate buffered saline having a pHrange of 5, 6 or 7 (as well as half and quarter values of these numberssuch as pH 5.5 and 5.25 etc.), in combination with limonene at aconcentration of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8% or 9% (as well as halfand quarter values of these numbers such as 1.5% and 1.25% etc.), incombination with sodium dodecyl sulfate at a concentration of 0.3%, 1%,2%, 3%, 4%, 5%, 6%, 7%, 8% or 9% (as well as half and quarter values ofthese numbers such as 1.5% and 1.25% etc.), in combination with a loweralkanol at a concentration of 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,10%, 11%, 12%, 13%, 14%, or 15% (as well as half and quarter values ofthese numbers such as 1.5% and 1.25% etc.). Certain specific embodimentsof this composition of matter further comprise a polymer matriximpregnated with an agent designed to facilitate in vivo implantation ofan apparatus such as a steroid or anti-coagulant.

An illustrative embodiment of the invention is a composition of mattercomprising a solution of phosphate buffered saline having a pH range of5-7, 3-5% limonene; 3-5% sodium dodecyl sulfate; and 3-15% loweralkanol. In certain embodiments of this composition, the lower alkanolis ethanol or n-butanol. Optionally in this composition, the solutioncomprises phosphate buffered saline having a pH of 6, 3-5% limonene;3-5% sodium dodecyl sulfate; and 1-3% n-butanol.

In some embodiments of the invention, the composition of matter furthercomprises a matrix impregnated with an elutable agent comprising asteroid, an anti-coagulant an antibiotic, or an anti-inflammatory agent.Optionally for example, the matrix is a polymer matrix impregnated withdexamethasone acetate. In one illustrative embodiment of the invention,the composition of matter further comprises a polymer matrix is adaptedfor use as part of a cardiac lead.

All numbers recited in the specification and associated claims (e.g. pH5 to pH 7; 1-9% limonene; 0.3-9% sodium dodecyl sulfate and 0.5-15%lower alkanol.) are understood to be modified by the term “about”.

B. Apparatus for Inhibiting Evaporation from a Vessel

A related embodiment of the invention is an apparatus that is used, forexample, to facilitate the practice of the above-noted methods byinhibiting the evaporation of dissolution media from the vessels inwhich elution is observed. In particular, the accuracy of quantificationof a drug such as dexamethasone in dissolution/elution tests greatlydepends upon maintaining the volume of the dissolution media.Evaporation is a significant issue due to the reduced amount ofdissolution media used for the drug coated devices. If the volumedecreases due to evaporation, it will lead to over estimation of thedrug content. This is a significant issue in extended release productswhich are tested for a longer period of time.

Typically, the apparatus includes a cap designed to cover the vessel andinhibit dissolution media loss through evaporation. This evaporationloss cap apparatus offers easy and accurate sampling, measuringtemperature and virtually no loss due to evaporation. Embodiments of theinvention are useful for example in the development, production andrelease of drug eluting products. For example, when a product will notbe approved by regulatory bodies without an appropriate elution methodfor studying possible process variability, the method can significantlydepend upon the integrity of the cover of the vessel. In illustrativeembodiments of the invention provided in the examples below, theapparatus reduces evaporation to less than 1% over a period of one week.This embodiment of the invention therefore demonstrates how dramaticallythe invention can reduce the evaporation of media from a dissolutionvessel.

FIG. 6 shows a typical embodiment of an apparatus of the invention, onedesigned to prevent loss due to evaporation from a fluid dissolutionvessel. This specific embodiment of the apparatus (10) comprises a cap(20) for engaging a vessel (30). The central diagram shows a group offour caps operative engaged with vessels and various interactiveelements of the apparatus. The diagram at the upper right shows the capnot engaged with a vessel and/or various interactive elements of theapparatus. In the embodiment of the invention shown in this figure, thecap has a first external side (40) and a second internal side (50) thatis exposed to a fluid contained in the vessel. The second side (50)comprises a conical member (60) that designed to direct a condensate(i.e. liquid formed by the condensation of a vapor or gas) that hascondensed from the fluid in the vessel onto the second side of the capback into the fluid. The cap includes a flange (70) disposed between thefirst external side and the second internal side of the cap. Thisembodiment shows a central port (80) disposed in the cap adapted toreceive a rotatable rod (90), where the material of the central port(typically Teflon) and the material of the rotatable rod are in closecontact so as to create a seal that inhibits escape of a materialcontained within the vessel into the external environment.

The rotatable rod in the embodiment of the invention shown in FIG. 6includes a fluid agitation member (170) at the distal end of the rodthat agitates fluid within the vessel. In this embodiment, the centralport (80) is disposed in a central washer (120) that is further disposedwithin a central washer port (130) on the cap. This embodiment shows asample port (100) disposed in the cap to allow a user to obtain a sampleof the solution from the vessel (or to introduce a composition into thevessel) via a cannula (not shown). In this embodiment, the sample port(100) is disposed in a sample port washer (110) that is further disposedin a sample washer port (160). The sample port washer (110) furtherincludes a cannula securing port (140) that receives a tightening screwmember (not shown) that can be used to secure a cannula inserted intothe sample port (100) at a desired position. This embodiment furthershows a temperature member port (150) adapted to allow a user tointroduce a temperature member that contacts and monitors thetemperature of the solution within the vessel. The temperature memberport (150) is adapted to receive a temperature port cap (210) that cancover the temperature port to prevent escape of a material within thevessel into the external environment. A sealing member (not shown) thatcontacts the vessel (30) that contains the fluid is typically disposedon the cap (20) so as to create a seal with the vessel that inhibitsescape of a material within the vessel into the external environmentwhen the cap is operatively engaged with the vessel. In addition, all ofthe interacting components in this embodiment are constructed to fittogether so as to create seals that inhibit escape of a material withinthe vessel into the external environment so that the apparatus inhibitsfluid loss from the vessel due to evaporation. This embodiment furthershows a clamp (180) that secures the cap to the vessel via a clamp screwmember (190) as well as a rack (200) constructed to hold a plurality ofvessels.

In some embodiments of the invention, the apparatus is described ashaving interacting components constructed to fit together so as tocreate seals that prevent escape of a material within the vessel intothe external environment so that the apparatus inhibits fluid loss fromthe vessel due to evaporation. In describing a device that “preventsescape of a material contained within the vessel into the externalenvironment”, this disclosure is intended for those of skill in this artwho understand that a seal that allows the escape of one molecule (or asmall number of molecules) within a vessel still prevents or essentiallyprevents the escape of a material contained within the vessel into theexternal environment. Further guidelines are provided in this regard toallow one of skill in the art to understand that prevents or essentiallyprevents escape of a material contained within the vessel into theexternal environment pertains to. These guidelines include anevaporation loss prevention cover apparatus that allows no more than10%, preferably no more than 5%, 4%, 3% or 2% and more preferably nomore than 1% of the fluid volume to escape from the vessel over a periodof 3, 4 or 5, (and optionally 7) days at 25, 37 or 45 degreescentigrade.

As noted above, a typical embodiment is an apparatus for covering avessel that contains a fluid, the apparatus comprising a cap forengaging the vessel (e.g. a circular cap), the cap having a firstexternal side and a second internal side that is exposed to a fluidcontained in the vessel, wherein the second side is cone shaped and/orcomprises a conical member that facilitates deposition of a condensatefrom the fluid back into the fluid. Typically, a flange is disposedbetween the first external side and the second internal side of the cap.In some embodiments of the invention, the flange engages an edge of thevessel so as to facilitate positioning of the apparatus in an operableorientation.

In certain embodiments of the invention, the cap includes a central portdisposed in the cap adapted to receive a rotatable rod that is used tostir a solution within the vessel. Optionally, the central port isdisposed in a central washer that is further disposed within a centralwasher port on the cap. Typically, the central port comprises a teflonmaterial (i.e. a low friction polytetrafluoroethylene polymer) disposedon a portion of the port that contacts the rotatable rod; and theportion of the central port that contacts the rotatable rod creates aseal with the rotatable rod that inhibits escape of a material containedwithin the vessel into the external environment. Some embodiments of theinvention include an apparatus kit that includes additional elements forpracticing methods of the invention such as a rotatable rod that can bedisposed in the central port, wherein the rotatable rod is disposablethrough the central port at the portion of the conical member closest tothe fluid so as to enter the portion of the vessel that contains thefluid so that the central rod acts as a fluid conduit for the condensatefrom the second side of the cap back into the fluid contained within thevessel. Typically, the rotatable rod includes a fluid agitation memberat the distal end of the rod that agitates fluid within the vessel.

In typical embodiments of the invention, the apparatus includes a sampleport disposed in the cap that is adapted to allow a user to obtain asample of the solution from within the vessel or to introduce acomposition into the vessel. Optionally, the sample port is disposed ina sample port washer that is further disposed within a sample washerport on the cap (e.g. as shown in FIG. 6). In one embodiment of theinvention, the sample port washer is disposed on the cap to guide andsupport a cannula that contacts the solution within the vessel.Typically, portions of the sample port washer that contact the cannulaand the portions of the sample port washer that contacts the samplewasher port create seals that inhibits escape of a material containedwithin the vessel into the external environment.

In some embodiments of the invention, the sample port is adapted toallow a user to introduce a temperature member (e.g. a thermometer,thermocouple or the like) that contacts and monitors the temperature ofthe solution within the vessel. In other embodiments of the invention,the apparatus further comprises a distinct temperature member port inthe cap that is adapted to allow a user to introduce a temperaturemember that monitors the temperature of the solution within the vesseland is also adapted to receive a temperature member port cap that coversthe temperature member port to inhibit escape of a material within thevessel into the external environment.

Typical embodiments of the invention include a sealing member disposedon the cap that contacts the vessel that contains the fluid so as tocreate a seal with the vessel that inhibits escape of a material withinthe vessel into the external environment when the cap is operativelyengaged with the vessel. In some embodiments of the invention, thesealing member is coupled to, adjacent to or supported by the flange. Avariety of sealing members and mechanisms known in the art can be usedas a sealing member. In certain embodiments of the invention, thesealing member is an O-ring. In some embodiments of the invention, thecap includes a groove or indentation for securing the sealing member.

In certain embodiments of the invention, a portion of the apparatus thatcontacts fluid in the vessel (e.g. fluid condensate) is comprised of amaterial that is resistant to degradation by a solution comprising:phosphate buffered saline at pH range of pH 5 to pH 7; 1-9% limonene;0.3-9% sodium dodecyl sulfate and 0.5-15% lower alkanol. In someembodiments of the invention this portion is made of Delrin. Similarly,in some embodiments of the invention, the O-ring is made of Viton

The apparatus can include a variety of other elements that facilitatemethods of observing elution of a compound from a composition. Forexample, certain embodiments of the apparatus can include one or moreclamps that secure the cap to the vessel. Other embodiments of theinvention include a sampling member adapted to allow a user to obtain asample of the solution from within the vessel or to introduce a sampleinto the vessel, wherein the sampling member comprises an angled cannulaadapted to obtain multiple fluid samples from the same location withinthe vessel. In such embodiments of the invention, the angle of theangled cannula adapted serves as a physical barrier to cannula movementand directs the cannula to the same place within the vessel over andover again so as to maintain consistency of sample collection. Inaddition, some embodiments of the invention include a rack to hold aplurality of capped vessels.

Typically, the components of the apparatus (e.g. the washers and washerports) are designed to fit together so as to create seals that preventescape of a material within the vessel into the external environment sothat the apparatus inhibits fluid loss from the vessel due toevaporation. Moreover, all portions of the apparatus that allow accessto the fluid within the vessel (e.g. the central and sample ports) canbe adapted to receive a cap member that covers the port so as to inhibitescape of a material within the vessel into the external environment. Inaddition, in typical embodiments of the invention, the cap is of unitaryconstruction, meaning that its material is made from a single cast ofmaterial and has no seams or joints that provide avenues for fluid loss.In an exemplary embodiment of the invention, the apparatus reduces fluidloss due to evaporation to less than 5%, 4%, 3%, 2% or 1% of the fluidcontained within the vessel over 7 days at 37 degrees centigrade. Inanother exemplary embodiment of the invention, the apparatus reducesfluid loss due to evaporation to less than 5%, 4%, 3%, 2% or 1% of thefluid contained within the vessel over 15 days at 37 degrees centigrade.

The apparatus disclosed above can be modified in order to adapt it foruse in a wide variety of contexts. In some embodiments of the invention,the sampling port can also act as a temperature measuring port byenabling the introduction of a thermo-couple into the vessel fortemperature measurements. In other embodiments, it has a separate portwhich acts as a temperature port. In some embodiments of the invention,a sampling cannula is introduced using the sampling port such that thepoint of sampling inside the vessel can be easily adjusted. The sampleintroduction port provides a correct and an easy way of introducing thesample into the dissolution vessel and significantly increases theaccuracy of the sampling and also the precision of sampling. Inaddition, this apparatus can be used to sample manually or can beadapted for use with an automatic sampler. A number of furtherembodiments of the invention will be readily apparent to those of skillin the art, including for example, elution methods of the invention thatare practiced using the apparatus of the invention as well as methods ofmaking the apparatus according to art accepted techniques.

The methods and apparatuses disclosed herein can be adapted for use in awide variety of procedures known in the art. All patent and literaturereferences (e.g. Shah et al., International Journal of Pharmaceutics 125(1995) 99-106; AAPS PharmSci 2002; 4 (2) article 7; AAPS PharmSci 2004;6 (1) Article 11; Guidance for Industry, Extended Release Oral DosageForms: Development, Evaluation, and Application of In Vitro/In VivoCorrelations, U.S. Department of Health and Human Services Food and DrugAdministration Center for Drug Evaluation and Research (CDER), September1997, BP 2; Palamakula et al., Preparation and In Vitro Characterizationof Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 UsingChiral Essential Oil Components, Pharmaceutical Technology OCTOBER 2004;Lawrence et al., Advanced Drug Delivery Reviews 45 (2000) 89-121 andU.S. Pat. Nos. 6,063,314; 4,819,662; 5,464,650; 5,609,629; 20040037886;and 20030208236) are incorporated by reference herein.

Embodiments of the invention include kits comprising a first container,a label on said container, and a composition contained within saidcontainer. Such kits include elution media components in one or morecontainers having a label, the label on said container, or a packageinsert included in said container indicates that the composition can beused to elute a composition form a matrix. Optionally the kit includes apremixed, ready to use elution media. Optionally the kit includesadditional elements such as an apparatus for using the media, anembodiment of which is shown in FIG. 6. Other embodiments of theinvention include a kit containing an apparatus for using the media, anembodiment of which is shown in FIG. 6, in the absence of elution mediacomponents.

EXAMPLES Example I Determination of Elution (In-Vitro Dissolution) ofDexamethasone Acetate Impregnated Product

Typical Methods and Materials Used to Practice the Invention

-   Typical Chemicals:-   (R)-(+)-Limonene, 97% (or above), Sigma-Aldrich Catalog #:    183164500ML, or equivalent-   Sodium Phosphate Monobasic (NaH2PO4), Sigma Catalog Number S8282, or    equivalent-   Sodium Phosphate Dibasic (Na2HPO4), Sigma Catalog Number S7907, or    equivalent Sodium Chloride-   Sodium Dodecyl Sulfate (Sigma Catalog #L6026 or equivalent)-   Acetonitrile, HPLC grade-   1 N Sodium Hydroxide Solution-   Process Water-   USP Dexamethasone Acetate Reference Standard-   Ammonium formate, Fluka Catalog #17843 or equivalent-   Formic Acid, Fluka Catalog #06450 or equivalent-   Sodium Hydroxide, Reagent Grade-   Hydrochloric Acid, Reagent Grade-   Potassium Chloride-   Potassium Phosphate, Monobasic-   1-Butanol    Typical Preparation of 0.5 M Potassium Phosphate Monobasic Solution

Weigh 6.8 grams of potassium phosphate monobasic into a 100 mLvolumetric flask. Dilute with process water to volume, and mix.

Typical Preparation of pH 6.0 Buffer Solution

Transfer 3.0 mL of 1N sodium hydroxide solution, 138 mL of 0.5 Npotassium chloride solution, and 50 mL of 0.5 M potassium phosphatemonobasic solution to a 1-L volumetric flask, dilute with process waterto volume, and mix.

Typical Preparation of Standard Diluent

Mix 500 mL of acetonitrile and 500 mL of pH 6.0 Buffet solution (1:1) toobtain 1-L standard diluent.

Typical Preparation of Media:

Preparation of 0.05M Phosphate Buffered Saline (PBS) Solution, pH 6.0:

This procedure is for preparing 4 L of 0.05M phosphate buffered saline(PBS). Other volumes of the PBS solution can be prepared byappropriately scaling down or scaling up the quantities of thematerials.

-   Weigh carefully 36±1.8 grams of Sodium Chloride into a 4 Liter    graduated cylinder.-   Add 3 L of process water to the cylinder.-   Stir until completely dissolved.-   Weigh carefully 22.8±1.1 grams of Sodium Phosphate Dibasic and add    to the same cylinder-   Stir until completely dissolved-   Weigh carefully 4.4±0.2 grams of Sodium Phosphate Monobasic and add    to the same cylinder.-   Stir until completely dissolved-   Adjust the pH of the solution to 6.0±0.1 using 1N Hydrochloric Acid    to reduce the pH. If necessary use 1N Sodium Hydroxide to increase    the pH.-   After adjusting the pH dilute with process water to 4 L volume.-   Transfer the solution to an appropriate bottle and label it as PBS    Media, pH 6.    Typical Preparation of Four Liters of 5% (w/w) (R)-(+)-Limonene    Media with 5% Sodium Dodecyl Sulfate and 2% 1-Butanol (Elution    Media):

This procedure is for preparing 4 L of the media. Other volumes can beprepared by changing the quantities of the materials appropriately.

-   Weigh carefully 200.0±2 grams of sodium dodecyl sulfate (SDS) into a    5 L beaker.-   Weigh carefully 200.0±6 grams of (R)-(+)-Limonene and transfer it    into the same beaker. Mix. Add 80.0±2 grams of 1-Butanol and then    mix.-   Weigh carefully 3520 g±192 g of PBS Media, pH 6 and add slowly to    the same beaker.-   Mix contents thoroughly using a hotplate stirrer and stir bar.-   Transfer the solution to a 5 L glass bottle and label appropriately.    Typical Standard Preparation

Weigh 100 mg Dexamethasone Acetate Reference Standard into a drying dishand dry under vacuum in a vacuum oven at 105° C. for 3 hours. (Driedpowder should can stored in a desiccator and used up to 7 days). Preparea standard solution of 100 μg/mL of dexamethasone acetate in StandardDiluent.

Elution Procedure

Typical Dissolution System Setup

-   Attach the low loss evaporation covers to the mini paddle and mount    the mini paddles to the drive unit. Attach the cannulas to the low    loss evaporation covers.-   Lower the drive unit holding the paddles and set the paddle heights    at 25 mm, the distance between the blade of the paddle and the    inside bottom of the vessel, using the 25 mm ball or any appropriate    gauge. This distance is maintained during the test.-   Add 75 mL of Elution Media to each mini vessel.-   Hold the low loss evaporation covers in place using the clamps.-   Adjust the cannula position such that the cannulas do not    touch/interfere with each other. Adjust the cannula by either    raising or lowering it such that the position of the cannula is    approximately midway between the top of the paddle and the surface    of the Elution Medium. Use the plastic screw on the probe that hosts    the cannula to tighten and maintain the position of the cannula.-   Seal the outer end of the cannulas (positioned outside the mini    vessel) using appropriate plugs or empty syringes or parafilm. If    this end is not sealed, it might lead to the loss of the media    through evaporation.-   Allow the Elution Media to equilibrate to 45±0.5° C.-   Measure and record the temperature of the media in all of the    vessels.-   Set the elution parameters according to Table 1A:

TABLE 1A Typical Elution Parameters Parameter Specification ApparatusUSP Apparatus 2 with mini vessels, mini paddles, covered by lowevaporation loss covers Media Information 5% R-(+)-Limonene, 5% SDS, 2%Butanol in PBS Buffer, pH 6.0 Media Volume 75 ml Media Temperature: 45.0± 0.5° C. Media 1 ml withdrawn/replaced Shaft Speed 100 rpm EvaporationControl Special low evaporation loss covers Typical Time Points* 6 hr,12 hr, Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 10, Day 12

-   Disengage the clamps that are holding the low loss evaporation    covers.-   Raise the drive unit carefully.-   Carefully drop each sample into a separate individual vessel. Make    sure the samples reach the bottom of the vessel.-   Lower the drive unit into place. Secure the drive unit in place.-   Ensure that the low loss evaporation covers are covering the mini    vessels.-   Immediately start rotating the paddle by using the menu on the    dissolution vessel and simultaneously start the timer.-   Secure the low loss evaporation covers using the clamps.-   At the sampling time points, remove the seal from the cannula.-   Use a 1 to 3 mL syringe to remove 1 mL of sample. Transfer the    sample into a HPLC vial of 2 mL capacity. Close the vial using an    appropriate lid. Each vessel will have a dedicated syringe and    cannula.-   Take 1 mL of fresh Elution Media in a clean, new syringe and    transfer it slowly into the mini vessel using the cannula.-   Seal the outer end of the cannulas (positioned outside the mini    vessel) using appropriate plugs or empty syringes or parafilm-   Repeat Steps for each sample.-   Analyze the pulled samples using chromatographic analysis such as    HPLC.

As an illustrative embodiment of the invention, a drug dissolutionmethod (in-vitro) was developed for the elution of Dexamethasone Acetate(Dexamethasone Acetate) from a typical CRD product (CRD=ControlledRelease Device). A variety of CRD products are known in the art, andinclude for example tips and rings used with electronic leads (see, e.g.U.S. Pat. Nos. 5,987,746, 6,567,704, and 7,184,839 and U.S. PatentApplication 20020138123, the contents of which are incorporated byreference). The method is required to support product development,quality control of the product and meet regulatory requirements (see,e.g. FDA Guidance for Industry (CDRH), “Guidance for the Submission ofResearch and Marketing Applications for Permanent Pacemaker Leads andfor Pacemaker Lead Adaptor 510 (k) Submissions”, November 2000; andBurgess et al., “Critical Quality and Performance Parameters forModified-Release Parenteral Dosage Forms”, Pharmacopeial Forum, 2005, 31(6), p. 1745).

Method Development

The steps in method development included adaptations of methods andmaterials known in the art, for example USP General Chapter <1092>,In-Process Revision, “The Dissolution Procedure: Development andValidation”, Pharmacopeial Forum, 2005, 31 (5), p. 1463; Burgess et al.,“Assuring Quality and Performance of Sustained and Controlled ReleaseParenterals: Workshop Report”, AAPS PharmSci, 2002, 4(2), article 7; andBurgess et al., “Assuring Quality and Performance of Sustained andControlled Release Parenterals: EUFEPS Workshop Report”, AAPS PharmSci,2004, 6(1), article 11. The development of the method included:

-   -   Preparation of Device for Elution Studies    -   Choice of Elution Parameters—effect of pH on solubility of drug,        choice of media & additives, volume of media    -   Evaluation of sink condition    -   Choice of apparatus along with its parameters    -   Choice of analytical method—for detection and quantification,        sampling points    -   Elution discrimination studies

A first step was to determine the solubility of the product usingstandard aqueous dissolution media, several of which are listed in theUSP (see, e.g. USP General Chapter <724>, “Drug Release”), literature(see, e.g. Noory et. al., (Food and Drug Administration—CDER), “Stepsfor Development of a Dissolution Test for Sparingly Water-soluble DrugProducts”, Dissolution Technologies, 2000, 7(1), Article 3) and the USFDA website (see, e.g. FDA website link for dissolution medias usingsearch terms: “accessdata.fda.gov/scripts/cder/dissolution/”). Theinitial run can allow evaluation of the effect of pH on the product. Ifthe product exhibited poor dissolution, then the need for a surfactant(below the critical micelle concentration forming emulsions) can beevaluated.

Dexamethasone acetate is a steroid, sparingly soluble in water.Dexamethasone Acetate is distributed in the polymer matrix asdispersion. The drug generally diffuses from the matrix into the fluidicsystem where the lead is placed. In typical embodiments of theinvention, it is important to use a dissolution medium that exhibitsgood thermodynamic compatibility with the polymer (see, e.g. Peppas etal., “Modeling of Drug Diffusion through Swellable Polymeric Systems”,Journal of Membrane Science, 1980, 7, p. 241-253; and Paul, D. R.,“Controlled Release Polymeric Formulations”, ACS Symposium Series,volume 33, ACS, Washington, 1976). A dissolution medium comprised of asurfactant forming emulsion (macro, micro or nano) would offer suchthermodynamic stability with the polymer. Use of surfactant isphysiologically relevant and can be successfully used for dissolutiontesting.

A literature survey showed that the elution of dexamethasone-elutingcardiac pacing electrodes is less than 19% in 24 days if PBS (withoutadditives) is used (see, e.g. Casas-Bejar et. al., “Medical ElectricalLeads and in-dwelling Catheters with enhanced Biocompatibility andBiostability”, United States Patent Publication, Publication #US20020138123 A1, Application Number 998536, Sep. 26, 2002) (PBS=PhosphateBuffered Saline). Another study conducted by Guidant Corporation, showedelution at about 10% in 30 days (see, e.g. Heil, R (GuidantCorporation), “In Vivo Comparison of Dexamethasone-eluting cardiacpacing electrode technologies with different release rates”, Proceed.Int'l. Symp. Control. Rel. Bioact. Mater., 2000, 27, p. 471). Thepercent elution was less than 7% in 10 days from the CRD leads when PBS(pH 5) without any additives was used. The information indicates thatthough the drug may be soluble in the buffered media at lowconcentrations (see sink condition evaluation below), the drugdissolution will be controlled by diffusion from the polymer.

Preparation of Device for Elution Studies

The drug eluting portion of samples were cut separately from the deviceand used for the purpose of testing. The CRD section was cut from thedevice such that the length of the section was approximately 1-2 cm.

Choice of Elution Parameters

To evaluate buffers with different pH, eleven milligrams ofDexamethasone Acetate was dissolved in 500 mL of media (different pHadjusted buffers). The stability of Dexamethasone Acetate with respectto pH followed this order: pH 3>pH 5≅acetate pH 5.7>water>pH 7>pH 9.This concentration was about 10 times the concentration that might beobserved if the drug from the typical device was completely eluted inabout 75 mL of media. This confirmed that the sink condition wasappropriate in the buffers above.

The next steps involved attempting to increase the elution by addingdifferent types of additives, capable of forming macro-emulsions, to themedia. This was in concurrence with the USP, US FDA and industryguidelines for performing elution on a sparingly soluble drug substance(see, e.g. USP General Chapter <1092>, “The Dissolution Procedure:Development and Validation”, Pharmacopeial Forum, 2005, 31 (5), p. 1463;FDA Guidance for Industry (CDER), “Extended Release Oral Dosage Forms:Development, Evaluation and Application of In Vitro/In VivoCorrelations”, September 1997; FDA Guidance for Industry (CDER),“Immediate Release Solid Oral Dosage Forms Scale-Up and PostapprovalChanges: Chemistry, Manufacturing, and Controls, In Vitro DissolutionTesting, and In Vivo Bioequivalence Documentation”, November 1995; 4.Burgess et al. “Assuring Quality and Performance of Sustained andControlled Release Parenterals: Workshop Report”, AAPS PharmSci, 2002,4(2), article 7; Burgess et al., “Assuring Quality and Performance ofSustained and Controlled Release Parenterals: EUFEPS Workshop Report”,AAPS PharmSci, 2004, 6(1), article 11, respectively). The suitability ofdifferent classes of surfactants, namely, anionic (e.g. sodium dodecylsulfate), cationic (e.g. Cetyl trimethyl ammonium bromide—CTAB) andnon-ionic (e.g. Solutol HS 15-poly-oxyethylene esters of12-hydroxystearic acid, Tween 80) as an additive to the elution mediawas evaluated. There was no significant increase in elution ofDexamethasone Acetate from the CRD. The maximum elution obtained wasabout 13% in 26 days in a media with the addition of 5% Solutol.

Since the surfactants did not increase the elution of DexamethasoneAcetate significantly, a two-tier elution method involving aco-surfactant was attempted. This followed a model similar to that usedin gelatin capsules (see, e.g. FDA website link for dissolution mediasusing search terms: “accessdata.fda.gov/scripts/cder/dissolution/”)(Dutasteride Soft Gelatin Capsule) and USP elution methods. However, dueto the two-tier nature of the media, this media evaluation wasdiscontinued.

In an effort to develop an accelerated elution method that would betterpenetrate the polymer matrix and that would increase diffusion (insteadof surface elution), media with additives that form a micro-emulsion ornano-emulsion were evaluated. The evaluations determined that Limonene,along with sodium dodecyl sulfate, provided a emulsion media that isthermodynamically stable (see e.g., Palamakula et al., “Preparation andIn-Vitro Characterization of Self-nanoemulsified Drug Delivery Systemsof Coenzyme Q10 using Chiral Essential Oil Components”, PharmaceuticalTechnology, 2004, 28(10), 74-88).

Micro-emulsions are widely used in drug delivery systems (see, e.g.Lawrence, M. J., Rees, G. D., “Micro-emulsion based Media as Novel DrugDelivery Systems”, Advanced Drug Delivery Reviews 45, 2000, p. 89-121).Advantages associated with micro-emulsions include their thermodynamicstability and ease of preparation. The existence of micro domains ofdifferent polarity within the same single-phase solution enables bothwater-soluble and oil-soluble materials to be solubilized, at the sametime if desired. It should be noted that the solubilisate partitionsbetween the micro-emulsion droplet and continuous phase and that whilethere may be a preferred site of solubilisation within themicro-emulsion droplet, the solubilisate may be located at one of anumber of sites. For example, the likely preferred sites ofincorporation of a lipophilic, water-insoluble drug into an oil/watermicro-emulsion are the disperse oil phase and/or hydrophobic tail regionof the surfactant molecule, while a water-soluble material would be mostlikely to be incorporated into the dispersed aqueous phase of awater-in-oil droplet. The attraction of micro-emulsion systems lies intheir ability to incorporate hydrophobic drugs into the apolar oil phasethereby enhancing their solubility (see, e.g. Paul, D. R., “ControlledRelease Polymeric Formulations”, ACS Symposium Series, volume 33, ACS,Washington, 1976).

The effect of media containing different concentrations of limonene andsodium dodecyl sulfate was studied. The media comprised of 3% Limoneneand 1% SDS in pH 6 PBS was found to be optimal for the elution of thetypical device. The media was able to accelerate the elution rate. Forexample, elution of Dexamethasone Acetate from CRD 2 was about ˜100% in8 days while it was more than 70% for the CRD 1 in 15 days. The mediawas also able to discriminate nominal lots from a process variation lot;(see sections below for the elution data of nominal and processvariation lots and the discrimination data). The elution plots wererepresentative of those observed with non-disintegrating type products(see, e.g. Hanson, R., Gray, V., Handbook of Dissolution Testing, Page.22, 3^(rd) Edition, Dissolution Technologies, Inc, Hockessin, Del.). Inan effort to enhance drug elution in stronger or higher crosslinkedmatrix, or to accelerate elution, media with components that providemore thermodynamic stability (i.e. a form of a nano-emulsion) wasdeveloped. One typical media comprised 5% R-(+)-Limonene, 5% SDS and 2%1-Butanol in pH 6 PBS.

Evaluation of Sink Conditions

The media (5% R-(+)-Limonene, 5% SDS and 2% 1-Butanol in pH 6 PBS) wasfound to meet the sink conditions, as outlined in elution methoddevelopment guidelines. This sink condition study proved that the drugwas fully soluble even at ten times the sample concentration expectedwhen the drug in the typical device is completely dissolved in 75 mLmedia.

Choice of Apparatus

The apparatus chosen for this method was USP Apparatus 2 (Paddles).During method development, it was found the elution rate was slightlyhigher in the Apparatus 2 than the Apparatus 1 (Basket). Due to the lowcontent of the drug in the device, mini vessels with mini paddles werechosen for the method. The apparatus was set at 100 rpm. A media volumeof 75 mL was found appropriate for the analytical methods detectioncapability and met the sink conditions. The media was maintained at 45°C.±0.5° C. The sample pull volume was 1 mL at each time point with mediacompensation, in line with elution guidelines.

Choice of Analytical Method of Quantification of Dexamethasone Acetate

The initial choice of analytical method was UV-Vis. However, due to thelow concentration of drug present in the material, HPLC with UVdetection was found to be the method of choice.

The mobile phase preparation and choice of the column were instructed inthe Dexamethasone Acetate monograph USP29-NF24. The mobile phase Aconsisted of pH 4.1 formate buffer and acetonitrile (3:2), and mobilephase B consisted of pH 4.1 formate buffer and acetonitrile (9:1). Thechromatographic column (USP L11) used was an Agilent Zorbax SB-Phenyl,4.6 mm×250 mm, 5 μm. A gradient was used with 1 mL/min flow rate. Therun time was about 70 minutes. The UV detection wavelength was 262 nm,where the method was found to be specific for quantification ofDexamethasone Acetate in the elution medium. The injection volume forstandard and samples was 100 μL. The drug was found to be stable in themedia for the length of the study.

Sampling Time Points and Elution Data

The elution of Dexamethasone Acetate from CRD from a nominal lot iscompared and presented in FIGS. 1A and 1B which show a typical plot ofelution of dexamethasone acetate from CRDs.

The elution pattern for CRD were similar to the profile of anon-disintegrating product (see, e.g. Hanson, R., Gray, V., Handbook ofDissolution Testing, Page. 22, 3^(rd) Edition, Dissolution Technologies,Inc, Hockessin, Del.). This profile was generally obtained where thedissolution rate was determined by the process of diffusion anddissolution.

The logarithmic plot of elution of Dexamethasone Acetate versus Time(See FIG. 2 which shows logarithmic plot of drug elution in CRD 1) showsthat the elution rate had essentially reached a plateau (asymptote) at 8days. The optimal sampling time points were chosen as 1, 3, 6 and 8 daysfor the typical CRD.

Three different nominal lots of the typical CRD were analyzed using therecommended elution method proposed. The results are presented in FIG.3. The results show the similarity in elution profile among the threedifferent nominal lots of the device.

Elution Discrimination Studies

The discriminating nature of the elution method was studied by testingthree lots of the same device. One lot was manufactured using thenominal process and each of the other two lots was manufactured withdifferent process variations. The elution method was capable ofdiscriminating between the nominal and process variation lots.

In the first study, using 6 samples from each lot, the elution ofDexamethasone Acetate from CRD 1 was about 77% in 15 days for thenominal lot, while the elution was about 56% in 15 days for the lot withfirst process variation. For the CRD 2, the elution of DexamethasoneAcetate was about 101% in 8 days for the nominal lot while the elutionwas about 84% in 8 days for the process variation lot. The results alsomet the criteria for discrimination for the similarity factor, F2, asspecified in the US FDA guidelines. For the CRD 1 and 2, the F2 values(see calculation formula below) were 41 and 45 respectively.

In the second study, the results obtained for the CRD 1 Samples from thenominal lot were compared with that of a second process variation lot.Six samples from each lot were used. Elution of Dexamethasone Acetatefrom CRD 1 was 77% in 15 days for the nominal lot while the elution wasabout 57% in 15 days for the second process variation lot. The resultsalso met the criteria for discrimination for the similarity factor, F2,as specified in the US FDA guideline (see, e.g. FDA Guidance forIndustry (CDER), “Extended Release Oral Dosage Forms: Development,Evaluation and Application of In Vitro/In Vivo Correlations”, September1997; and FDA Guidance for Industry (CDER), “Immediate Release SolidOral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry,Manufacturing, and Controls, In Vitro Dissolution Testing, and In VivoBioequivalence Documentation”, November 1995). The calculated F2 valuewas 45. The elution data obtained during discriminating studies arepresented in FIGS. 4 and 5.

In a third study, using the media described in Table 1A, CRD 1 wassubjected to elution studies; the F2 values were 47 and 44 respectivelyfor two process variations. The elution data obtained duringdiscriminating studies are presented in FIG. 7A.

In a fourth study, using the media described in Table 1A, CRD 2 wassubjected to elution studies; the F2 value was 46 for the processvariation. The elution data obtained during discriminating studies arepresented in FIG. 7B

As per the elution guidelines the F2 factor should be less than 50 toconsider the method to be discriminating (see, e.g. FDA Guidance forIndustry (CDER), “Extended Release Oral Dosage Forms: Development,Evaluation and Application of In Vitro/In Vivo Correlations”, September1997; and FDA Guidance for Industry (CDER), “Immediate Release SolidOral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry,Manufacturing, and Controls, In Vitro Dissolution Testing, and In VivoBioequivalence Documentation”, November 1995). The F2 results calculatedabove demonstrate that the method is discriminating.Formula for F2 Calculation:F2=50 LOG {[1+1/nΣ ^(n) _(t=1)(R _(t) −T _(t))²]^(−0.5)×100}

Where R_(t) and T_(t) are the percent dissolved at each time point]

Conclusion

The in-vitro dissolution method summarized below was found to besuitable for testing drug elution from steroid eluting products such asleads. The elution media was found to be discriminating between thenominal samples and samples that were manufactured with processvariations. The details of the elution method are summarized in Table 1Bbelow:

TABLE 1B Typical Second Elution method Summary of Method Elution ofDexamethasone Acetate from Steroid Eluting Products Apparatus ModifiedUSP Apparatus 2 with mini-vessels and mini-paddles Elution Media 3%R-(+)-Limonene and 1% SDS in pH 6 PBS Media Volume 75 mL Paddle Speed100 RPM Water Bath Temperature 37.0° C. ± 0.5° C. Sampling Time PointsDays 1, 3, 6 and 8 Sample Volume 1 mL with media replacement

Example 2 Media Embodiments Comprising a Lower Alkanol Cosolvent

Embodiments of the invention include elution media comprising acosolvent in the form of a lower alkanol and methods for using thismedia. A typical media embodiment having a cosolvent includes forexample 5% R (+) Limonene, 5% Sodium Dodecyl Sulfate, 2% n-Butanol inPBS pH 6.0. This media embodiment was used in the studies shown in FIGS.7B and 7C. While this is a typical recipe, media embodiments of theinvention can include a wide variety of concentration ranges for thevarious constituents in the media composition, for example thoseincluded in TABLE 1C below.

TABLE 1C % R (+) Limonene % SDS % Alcohol 7 5 0.5 - Butanol 3 1 0.5 -Butanol 3 1 2 - Butanol 5 5 2 - Butanol 3 1 5 - Butanol 5 5 5 - Ethylalcohol 2 1 0 3 1 0 4 2 0 5 2 0 5 5 0 6 3 0 7 1 0 7 2 0 7 5 0 8 8 0 5 70 3 7 0 1% R (+) Limonene + 1 0 1% S (−) Limonene

Those of skill in the art can readily make such media compositions usingcommercially available reagents. In one illustrative embodiment forexample comprising 100 ml of a media composition comprising 5% R (+)Limonene, 5% Sodium Dodecyl Sulfate, and 5% n-Butanol in PBS, 5% valuereflects the value of the total constituent (e.g. 5 grams of alcohol+5grams of limonene+5 grams of SDS+85 grams of PBS solution).

Typical conditions and/or methodological steps (e.g. temperature,agitation etc.) that can be used with this cosolvent media are includedin TABLE 1A above.

All patent and literature references cited in the present specificationare hereby incorporated by reference in their entirety.

1. A method for observing the elution of a compound from a matrixcomprising the compound into a solution, the method comprising exposingthe matrix comprising the compound to a solution, wherein the solutioncomprises: phosphate buffered saline having a pH range of pH 5 to pH 7;1-9% limonene; 0.3-9% sodium dodecyl sulfate; and 0.5-15% lower alkanol;and assaying the solution for the presence of the compound so as toobserve the elution of the compound from the matrix into the solution.2. The method of claim 1, wherein the lower alkanol is ethanol orn-butanol.
 3. The method of claim 1, wherein the solution comprises:phosphate buffered saline having a pH of 6; 3-5% limonene; 3-5% sodiumdodecyl sulfate; and 1-3% n-butanol.
 4. The method of claim 1, furthercomprising performing the method on a plurality of matrices made by aprocess designed to produce a plurality of matrices that elute thecompound at the same rate and comparing the elution rates of two or moreof plurality of matrices to determine if the two or more matrices havethe same or different elution rates.
 5. The method of claim 1, whereinthe solution is assayed for the presence of the compound using highperformance liquid chromatography (HPLC).
 6. The method of claim 5,wherein the matrix comprising the compound is a polymer matrix havingthe compound blended therein.
 7. The method of claim 6, wherein thematrix comprises a biomedical grade silicone polymer.
 8. The method ofclaim 1, wherein the compound comprises a steroid, an anti-coagulant anantibiotic, or an anti-inflammatory agent.
 9. The method of claim 8,wherein the compound is dexamethasone acetate.
 10. The method of claim1, wherein the matrix comprising the compound is implantable.
 11. Themethod of claim 1, further comprising observing elution at a solutiontemperature of between 25 and 45 degrees centigrade.
 12. The method ofclaim 1 further comprising agitating the solution with a stirringdevice.
 13. The method of claim 1, wherein the volume of the solution isbetween 50 and 150 milliliters.
 14. The method of claim 1, furthercomprising using a solution in the method that is selected for itsability to elute at least 50% of dexamethasone acetate impregnatedwithin a polymeric silicon in 72 hours at 45 degrees centigrade.
 15. Acomposition of matter comprising a solution of: phosphate bufferedsaline having a pH range of pH 5 to pH 7; 1-9% limonene; 0.3-9% sodiumdodecyl sulfate; and 0.5-15% lower alkanol.
 16. The composition ofmatter of claim 15, wherein the lower alkanol is ethanol or n-butanol.17. The composition of matter of claim 15, wherein the solutioncomprises: phosphate buffered saline having a pH of 6; 3-5% limonene;3-5% sodium dodecyl sulfate; and 1-3% n-butanol.
 18. The composition ofmatter of claim 15, further comprising a matrix impregnated with anelutable agent comprising a steroid, an anti-coagulant an antibiotic, oran anti-inflammatory agent.
 19. The composition of matter of claim 18,wherein the matrix is a polymer matrix impregnated with dexamethasoneacetate.
 20. The composition of matter of claim 19, wherein the matrixis adapted for use as part of a cardiac lead.